127 related articles for article (PubMed ID: 2140825)
1. Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).
Maughan TS; Newman HF; Bleehen NM; Ward R; Workman P
Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1151-6. PubMed ID: 2140825
[TBL] [Abstract][Full Text] [Related]
2. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Newman HF; Ward R; Workman P; Bleehen NM
Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1073-83. PubMed ID: 2972667
[TBL] [Abstract][Full Text] [Related]
3. A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Bleehen NM; Newman HF; Maughan TS; Workman P
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1093-6. PubMed ID: 2539346
[TBL] [Abstract][Full Text] [Related]
4. The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study.
Bleehen NM; Maughan TS; Workman P; Newman HF; Stenning S; Ward R
Radiother Oncol; 1991; 20 Suppl 1():137-42. PubMed ID: 1826962
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
Newman HF; Bleehen NM; Workman P
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1113-6. PubMed ID: 2943709
[TBL] [Abstract][Full Text] [Related]
6. Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Newman HF; Bleehen NM; Ward R; Workman P
Int J Radiat Oncol Biol Phys; 1988 Sep; 15(3):677-84. PubMed ID: 2843488
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitization by the combination of etanidazole (SR-2508) and pimonidazole (Ro 03-8799) in human tumor xenografts.
Taghian A; Lespinasse F; Guichard ME
Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1535-40. PubMed ID: 1834621
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of 2-nitroimidazole hypoxic cell radiosensitizers in rodent peripheral nervous tissue.
Sasai K; Shibamoto Y; Takahashi M; Ito T; Nishimoto S; Abe M
Int J Radiat Biol; 1990 May; 57(5):971-80. PubMed ID: 1970998
[TBL] [Abstract][Full Text] [Related]
9. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Noll L; Hancock S; Phillips TL
Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):389-93. PubMed ID: 2154420
[TBL] [Abstract][Full Text] [Related]
10. Accelerated elimination of pimonidazole following microsomal enzyme induction in mice: a possible approach to reduced neurotoxicity of the pimonidazole-etanidazole combination.
Workman P
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1011-4. PubMed ID: 2522916
[TBL] [Abstract][Full Text] [Related]
11. Additivity of radiosensitization by the combination of SR 2508 (etanidazole) and Ro 03-8799 (pimonidazole) in a murine tumor system.
Honess DJ; Wasserman TH; Workman P; Ward R; Bleehen NM
Int J Radiat Oncol Biol Phys; 1988 Sep; 15(3):671-5. PubMed ID: 2971028
[TBL] [Abstract][Full Text] [Related]
12. Logistics in designing clinical trials for etanidazole (SR 2508): an RTOG experience.
Lee DJ; Phillips TL; Coleman CN; Cosmatos D; Davis LW; Wasserman TH; Marcial VA; Rubin P
Int J Radiat Oncol Biol Phys; 1992; 22(3):569-71. PubMed ID: 1531215
[TBL] [Abstract][Full Text] [Related]
13. Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study.
Coleman CN; Noll L; Howes AE; Harris JR; Zakar J; Kramer RA
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1085-7. PubMed ID: 2522919
[TBL] [Abstract][Full Text] [Related]
14. Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study.
Coleman CN; Noll L; Riese N; Buswell L; Howes AE; Loeffler JS; Alexander E; Wen P; Harris JR; Kramer RA
Int J Radiat Oncol Biol Phys; 1992; 22(3):577-80. PubMed ID: 1531217
[TBL] [Abstract][Full Text] [Related]
15. Ro 03-8799: preferential relative uptake in human tumor xenografts compared to a murine tumor: comparison with SR-2508.
Lespinasse F; Thomas C; Bonnay M; Malaise EP; Guichard M
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1105-9. PubMed ID: 2522920
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of the combined hypoxic cell radiosensitizers, Ro 03-8799 and SR 2508: a preliminary report of single-dose toxicity, pharmacokinetics and tumour concentrations.
Newman HF; Bleehen NM; Workman P
Br J Radiol; 1986 Apr; 59(700):423-5. PubMed ID: 2938660
[No Abstract] [Full Text] [Related]
17. The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer.
Coleman CN; Buswell L; Noll L; Riese N; Rose MA
Int J Radiat Oncol Biol Phys; 1992; 22(3):565-8. PubMed ID: 1310497
[TBL] [Abstract][Full Text] [Related]
18. Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment.
Workman P; Ward R; Maughan TS; Newman HF; Bleehen NM
Int J Radiat Oncol Biol Phys; 1989 Jul; 17(1):177-81. PubMed ID: 2526107
[TBL] [Abstract][Full Text] [Related]
19. Hypoxic cell radiosensitizers: expectations and progress in drug development.
Coleman CN
Int J Radiat Oncol Biol Phys; 1985 Feb; 11(2):323-9. PubMed ID: 3156109
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule.
Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Hirst VK; Hancock S; Phillips TL
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1105-8. PubMed ID: 3017904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
